



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 31/445, 31/44, 31/535, 31/40, 31/38, 31/20, 31/18, 31/415, 31/195, 31/135</b>		A1	(11) International Publication Number: <b>WO 00/02561</b> (43) International Publication Date: 20 January 2000 (20.01.00)
(21) International Application Number: <b>PCT/US99/15947</b>		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 13 July 1999 (13.07.99)			
(30) Priority Data: 60/092,570 13 July 1998 (13.07.98) US			
(71) Applicant (for all designated States except US): UNIVERSITY OF SOUTH FLORIDA [US/US]; 3515 E. Fletcher Avenue, Tampa, FL 33613 (US).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): PARIS, Daniel [FR/US]; 15210 Amberly Drive #1125, Tampa, FL 33647 (US). TOWN, Terrence, C. [US/US]; 15215 Livingston Avenue #167, Lutz, FL 33549 (US). MULLAN, Michael, J. [US/US]; 15209 Plantation Oaks Drive, Tampa, FL 33647 (US).			
(74) Agents: KOHN, Kenneth, I. et al.; Kohn & Associates, Suite 410, 30500 Northwestern Highway, Farmington Hills, MI 48334 (US).			
(54) Title: MODULATION OF THE PHOSPHOLIPASE A2 PATHWAY AS A THERAPEUTIC			
(57) Abstract			
<p>There is provided a method of modifying vasoactivity by regulating a soluble A<math>\beta</math> pro-inflammatory pathway. Also provided is a method of modifying inflammatory reactions in microglia and neurons by regulating a soluble A<math>\beta</math> pro-inflammatory pathway. A method of treating patients with vascular disease by modifying an intracellular soluble A<math>\beta</math> pro-inflammatory pathway is also provided. A pharmaceutical composition consisting essentially of an effective amount of a soluble A<math>\beta</math> pro-inflammatory pathway regulator in a pharmaceutically effective carrier is also provided.</p>			